The Collaboration In COPD ExaceRbatiOns (CICERO) Clinical Research Collaboration (CRC) has secured the funds to begin a pan-European prospective interventional cohort study ‘CATALINA’ as part of its ambitious three-year project.
The project’s objective is to understand and improve outcomes in severe COPD exacerbations across Europe, in collaboration with founding funding partners AstraZeneca and Roche.
The CATALINA study will collect prospective, standardised, longitudinal data and biological samples in 20 European centres, obtained from 1,000 enrolled patients hospitalised for an acute COPD exacerbation with a one-year follow-up. This study will serve as an exploratory dataset to design future interventions studies for specific patient subgroups.
The CATALINA study is a key element of the CICERO CRC, which is a pan-European multi-centre network aiming to create a unique platform which allows expert clinical researchers, young investigators, industry partners and patient and public representatives to advance scientific understanding, clinical management and patient outcomes in severe COPD exacerbations.